[1]黄明民,李 丹,李 凰,等.AECOPD 患者血清FOXM1 和CCR5 水平与肺功能及预后的预测价值研究[J].现代检验医学杂志,2024,39(03):176-182.[doi:10.3969/j.issn.1671-7414.2024.03.030]
　HUANG Mingmin,LI Dan,LI Huang,et al.Predictive Value of Serum FOXM1 and CCR5 Levels in AECOPD Patients with Lung Function and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(03):176-182.[doi:10.3969/j.issn.1671-7414.2024.03.030]
点击复制

AECOPD 患者血清FOXM1 和CCR5 水平与肺功能及预后的预测价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
176-182
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Predictive Value of Serum FOXM1 and CCR5 Levels in AECOPD Patients with Lung Function and Prognosis
文章编号:
1671-7414（2024）03-176-07
作者:
黄明民; 李 丹; 李 凰; 付收硕; 林春龙
（岳阳市人民医院呼吸内科，湖南岳阳 414022）
Author(s):
HUANG Mingmin; LI Dan; LI Huang; FU Shoushuo; LIN Chunlong
(Department of Respiratory，Yueyang People’s Hospital，Hunan Yueyang 414022，China)
关键词:
慢性阻塞性肺疾病急性加重期; 肺功能; 叉头框蛋白M1; CC 趋化因子受体5
分类号:
R563；R392.11
DOI:
10.3969/j.issn.1671-7414.2024.03.030
文献标志码:
A
摘要:
目的 探讨叉头框蛋白M1（fork head box M1，FOXM1），CC 趋化因子受体5（CC chemokine receptor 5，CCR5）对老年慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease，AECOPD) 患者肺功能及预后的评估价值。方法 选取2022 年1 月～ 2023 年1 月岳阳市人民医院收治的128 例AECOPD 患者作为急性加重期组，选择同期收治的135 例稳定期COPD 患者作为稳定期组，年龄、性别相仿的120 例健康体检志愿者为对照组。采用酶联免疫吸附法（ELISA）检测血清中FOXM1 和CCR5 的表达水平，肺活量计检测肺功能指标。Pearson法分析AECOPD 患者血清FOXM1，CCR5 与肺功能指标的相关性；多因素Logistic 回归分析筛选AECOPD 患者预后影响因素，受试者工作特征（receiver operator characteristic，ROC）曲线分析FOXM1，CCR5 水平对AECOPD 患者预后不良的评估价值。结果 AECOPD 组患者和稳定期组患者血清中CCR5（49.36±12.31 ng/ml，34.25±8.87 ng/ml），FOXM1（40.21±10.74 pg/ml，23.38±5.77 pg/ml）水平较对照组（14.55±4.58 ng/ml，15.06±3.55 pg/ml）明显升高，FEV1（1.15±0.13 L，1.67±0.19 L），FVC（2.93±0.30 L，3.28±0.36 L），FEV1/FVC（39.25% ± 3.97 %，50.91%± 5.01 %）较对照组（1.95±0.26 L，3.57±0.44 L，54.62% ±5.20 %）下降，差异具有统计学意义（F=111.034~641.907，均P<0.05）。血清FOXM1，CCR5 水平随着肺功能分级加重而逐渐升高，肺功能指标FEV1，FVC 水平随着肺功能分级加重而逐渐降低，差异具有统计学意义（F=31.27，49.37；42.72，29.48，均P<0.05）。血清FOXM1，CCR5 表达与FEV1，FVC，FEV1/FVC 呈负相关（r=-0.639 ～‐0.479，均P<0.05）。Logistic 回归分析发现，CCR5[OR(95%CI): 3.380（1.944~5.876）]，FOXM1[OR（95%CI): 5.711（3.175~10.273）]，APACHE Ⅱ评分[OR（95%CI): 2.132（1.243~3.60）]，肺功能分级[OR（95%CI): 2.017（1.007~4.037）] 为预后不良发生的危险因素（均P<0.05），FEV1[OR（95%CI): 0.649（0.441~0.955）]，FVC[OR（95%CI): 0.120（0.073~0.198）] 为预后不良发生的保护因素（均P<0.05）。ROC 曲线结果显示，血清FOXM1，CCR5 水平预测AECOPD 患者预后不良的曲线下面积（area under curve，AUC）分别为0.821，0.831，二者联合预测的AUC 为0.895，高于单一指标检测（Z=2.800，2.654，均P ＜ 0.05）。结论 FOXM1 和CCR5在AECOPD 患者血清中均呈高水平，早期检测二者可作为评估AECOPD 患者肺功能及预后不良的血清标志物。
Abstract:
Objective To explore the evaluation value of forkhead box M1 (FOXM1) and CC chemokine receptor 5 (CCR5) on lung function and prognosis in elderly patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 128 AECOPD patients admitted to Yueyang People’s Hospital from January 2022 to January 2023 were collected as the acute exacerbation group, 135 stable COPD patients admitted at the same time were regarded as the stable phase group, and 120 health examination volunteers of similar age and gender were regarded as the control group. Enzyme-linked immunosorbent assay (ELISA) was applied to detect the expression levels of FOXM1 and CCR5 in serum, and the vital capacity meter was applied to measure pulmonary function. Pearson method was applied to analyze the correlation between serum FOXM1, CCR5 and lung function indicators in AECOPD patients. Multivariate logistic regression analysis was applied to screen prognostic factors for AECOPD patients. The evaluation value of FOXM1 and CCR5 levels in evaluating poor prognosis of AECOPD patients was analyzed by receiver operating characteristic (ROC) curve. Results In the serum of patients in the AE COPD group and stable stage group, the levels of CCR5 (49.36 ± 12.31 ng/ml, 34.25 ± 8.87 ng/ml) and FOXM1 (40.21 ±10.74 pg/ml, 23.38 ± 5.77 pg/ml) were significantly higher than those in the control group (14.55 ± 4.58 ng/ml, 15.06 ± 3.55 pg/ml), while FEV1 (1.15 ± 0.13 L, 1.67 ± 0.19 L), FVC (2.93 ± 0.30 L, 3.28 ± 0.36 L) and FEV1/FVC (39.25 % ± 3.97%, 50.91% ± 5.01%) were lower than those in the control group (1.95 ± 0.26 L, 3.57 ± 0.44 L, 54.62% ± 5.20%), with significant differences (F=111.034~641.907, all P<0.05). The levels of serum FOXM1 and CCR5 were gradually increased with the aggravation of lung function grading, while the levels of lung function indicators FEV1 and FVC were gradually decreased with the aggravation of lung function grading，and the differences were statistically significant (F=31.27, 49.37；42.72, 29.48, all P<0.05). The serum levels of FOXM1 and CCR5 were negatively correlated with FEV1, FVC and FEV1/FVC (r= -0.639 ～ -0.479, all P<0.05). Logistic regression analysis found that CCR5[OR(95%CI): 3.380(1.944~5.876)], FOXM1[OR(95%CI): 5.711(3.175~10.273)], APACHE II score[OR(95%CI): 2.132(1.243~3.660)], and lung function grading [OR(95CI): 2.017(1.007~4.037)] were all risk factors for poor prognosis (all P<0.05), while FEV1[OR(95%CI): 0.649(0.441~0.955)] and FVC[OR(95%CI): 0.120(0.073~0.198)] were protective factors for poor prognosis (all P<0.05). ROC curve results showed that the areas under the curve (AUC) of serum FOXM1 and CCR5 levels in predicting poor prognosis in AECOPD patients were 0.821 and 0.831, respectively. The AUC predicted by the combination of the two was 0.895, which was higher than that detected by a single indicator（Z=2.800，2.654，all P ＜ 0.05）. Conclusion FOXM1 and CCR5 were both high levels in the serum of AECOPD patients. Early detection of them can serve as serum markers for evaluating lung function and poor prognosis in AECOPD patients.

参考文献/References:

[1] GU Yu, YE Xianping, WANG Yu, et al. Clinical features and prognostic analysis of patients with Aspergillus isolation during acute exacerbation of chronic obstructive pulmonary disease[J]. BMC Pulmonary Medicine, 2021, 21(1): 69.
[2] ZHAO Xin, WU Yueqin. Correlations of silent information regulator of transcription 1 (SIRT1) expression, inflammatory factors, and oxidative stress with pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)[J]. Medical Science Monitor, 2021, 27:e929046.
[3] YU Suyun, XUE Min, YAN Zhijun, et al. Correlation between TNF- α -308 and +489 gene polymorphism and acute exacerbation of chronic obstructive pulmonary diseases[J]. BioMed Research International,2021, 2021: 6661281.
[4] HUANG Shijun, DING Zhangnan, XIANG Huixian,et al. Association between serum S100A8/S100A9 heterodimer and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Lung, 2020, 198(4): 645-652.
[5] 江璇, 叶焰, 丘梅清, 等. 支气管哮喘患者血清CCR5, eotaxin 水平变化及其对免疫Th17, Treg 细胞平衡的影响[J]. 免疫学杂志, 2021, 37(11): 1001-1006. JIANG Xuan, YE Yan, QIU Meiqing, et al. Changes in serum levels of CCR5 and eotaxin in bronchial asthma patients and their effects on Th17/Treg balance[J].Immunological Journal, 2021, 37(11): 1001-1006.
[6] 慢性阻塞性肺疾病急性加重(AECOPD) 诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD) 诊治中国专家共识(2017 年更新版) [J] . 国际呼吸杂志,2017,37(14): 1041-1057. Expert Group Opinion on Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Expert Consensus on acute exacerbation of chronic obstructive pulmonary disease in China (Updated 2017) [J]. International Journal of Respiration, 2017, 37(14): 1041-1057.
[7] 方利文, 包鹤龄, 王宝华, 等. 中国居民慢性阻塞性肺疾病监测内容与方法概述[J]. 中华流行病学杂志,2018, 39(5): 546-550. FANG Liwen, BAO Heling, WANG Baohua, et al. A summary of item and method of national chronic obstructive pulmonary disease surveillance in China[J].Chinese Journal of Epidemiology, 2018, 39(5): 546-550.
[8] WU C T, LI G H, HUANG C T, et al. Acute exacerbation of a chronic obstructive pulmonary disease prediction system using wearable device data, machine learning, and deep learning: development and cohort study[J]. JMIR mHealth and uHealth, 2021, 9(5):e22591.
[9] 马大文, 王宏俊, 胡莎莎. NLR, PLR 联合MPV 预测老年慢性阻塞性肺疾病患者急性加重期近期预后不良的价值[J]. 检验医学, 2022, 37(9): 850-854. MA Dawen, WANG Hongjun, HU Shasha. Value of NLR and PLR combined MPV on poor short-term prognosis in elderly patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Laboratory Medicine, 2022, 37(9): 850-854.
[10] FU Zhen, JIANG Hongwei, XU Zhongyu, et al. Objective secondhand smoke exposure in chronic obstructive pulmonary disease patients without active smoking: the U.S. National Health and Nutrition Examination Survey (NHANES) 2007-2012[J]. Annals of Translational Medicine, 2020, 8(7): 445.
[11] 龙借帆, 李翠, 高元标, 等. 联合检测血清SIRT1 和CTRP5 水平对慢性阻塞性肺疾病急性加重期患者预后的预测价值研究[J]. 现代检验医学杂志, 2022,37(3): 162-166, 176. LONG Jiefan, LI Cui, GAO Yuanbiao, et al. Prognostic value of combined detection of serum SIRT1 and CTRP5 levels in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 162-166,176.
[12] KABBACH E Z, HEUBEL A D, DA LUZ GOULART C, et al. Association of exercise capacity and endothelial function in patients with severe exacerbations of chronic obstructive pulmonary disease[J]. Scientific Reports, 2021, 11(1): 461.
[13] SUN Desheng, LIU Hongyan, OUYANG Yao, et al. Serum levels of gamma-glutamyltransferase during stable and acute exacerbations of chronic obstructive pulmonary disease[J]. Medical Science Monitor, 2020,26: e927771.
[14] ZENG Zhen, LAN Tianxia, WEI Yuquan, et al. CCL5/CCR5 axis in human diseases and related treatments[J].Genes & Diseases, 2022, 9(1): 12-27.
[15] FERRERO M R, GARCIA C C, DUTRA DE ALMEIDA M, et al. CCR5 antagonist maraviroc inhibits acute exacerbation of lung inflammation triggered by influenza virus in cigarette smoke-exposed mice[J]. Pharmaceuticals (Basel, Switzerland), 2021,14(7): 620.
[16] YUAN Jing, REN Hanyun. C-C chemokine receptor 5 and acute graft-versus-host disease[J]. Immunity Inflammation and Disease, 2022, 10(9): e687.
[17] 牛立远, 刘会雪, 史立彬. 急性脑梗死患者血清CCR5 和miR-211-5p 表达水平及其临床意义[J]. 现代检验医学杂志, 2023, 38(1): 128-134. NIU Liyuan, LIU Huixue, SHI Libin. Expression levels and their clinical significance of serum CCR5 and miR-211-5p in patients with acute cerebral infarction[J].Journal of Modern Laboratory Medicine, 2023, 38(1):128-134.
[18] YAN Jun, XU Weilin, LENAHAN C, et al. CCR5 activation promotes NLRP1-Dependent neuronal pyroptosis via CCR5/PKA/CREB pathway after intracerebral hemorrhage[J]. Stroke, 2021, 52(12):4021-4032.
[19] JOO D H, LEE K H, LEE C H, et al. Developmental endothelial locus-1 as a potential biomarker for the incidence of acute exacerbation in patients with chronic obstructive pulmonary disease[J]. Respiratory Research, 2021, 22(1): 297.
[20] XING Shan, TIAN Zhi, ZHENG Wenying, et al. Hypoxia downregulated miR-4521 suppresses gastric carcinoma progression through regulation of IGF2 and FOXM1[J]. Molecular Cancer, 2021, 20(1): 9.
[21] MADHI H, LEE J S, CHOI Y E, et al. FOXM1 inhibition enhances the therapeutic outcome of lung cancer immunotherapy by modulating PDL1 expression and cell proliferation[J]. Advanced Science(Weinheim, Baden-Wurttemberg Germany) ,2022, 9(29): e2202702.
[22] LIANG Shengkai, HSU C C, SONG H L, et al. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis[J]. Oncogene,2021, 40(30): 4847-4858.
[23] 高健. 支气管哮喘患儿血清小窝蛋白-1 水平和叉头框蛋白M1 基因表达与气道重塑的相关性[J]. 新乡医学院学报, 2022, 39(2): 155-159. GAO Jian. Correlation between serum caveolin-1,forkhead box M1 gene expression and airway remodeling in children with bronchial asthma[J].Journal of Xinxiang Medical College, 2022, 39(2): 155-159.

相似文献/References:

[1]王媛a,田应选b,杨春芳a.血清炎性标志物对老年慢性阻塞性肺疾病的临床诊断价值研究[J].现代检验医学杂志,2015,30(05):121.[doi:10.3969/j.issn.1671-7414.2015.05.037]
　WANG Yuana,TIAN Ying-xuanb,YANG Chun-fanga.Study on the Value of Three Serum Biomarkers for Diagnosis Elderly Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2015,30(03):121.[doi:10.3969/j.issn.1671-7414.2015.05.037]
[2]崔雨佳,刘　忠.外周血嗜酸性粒细胞水平与慢性阻塞性肺疾病急性加重期患者临床预后的相关性分析[J].现代检验医学杂志,2020,35(03):129.[doi:10.3969/j.issn.1671-7414.2020.03.035]
　CUI Yu-jia,LIU Zhong.Relationship between Peripheral Blood Eosinophil Level and the Prognosis of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2020,35(03):129.[doi:10.3969/j.issn.1671-7414.2020.03.035]
[3]陈志勇a,罗世林a,张　健b,等.慢阻肺患者血清IL-17，IL-27和IL-33水平表达及与不同临床分期FeNO和肺功能的相关性研究[J].现代检验医学杂志,2021,36(04):152.[doi:10.3969/j.issn.1671-7414.2021.04.033]
　CHEN Zhi-yonga,LUO Shi-lina,ZHANG Jianb,et al.Expression of Serum IL-17, IL-27 and IL-33 in Patients with ChronicObstructive Pulmonary Disease and Its Correlation with FeNO and LungFunction in Different Clinical Stages[J].Journal of Modern Laboratory Medicine,2021,36(03):152.[doi:10.3969/j.issn.1671-7414.2021.04.033]
[4]李　颖,任炳臣,韩晓庆,等.支气管哮喘患者血清MicroRNA-145水平表达与肺功能、气道重塑及Th1/Th2平衡的关系分析[J].现代检验医学杂志,2021,36(05):133.[doi:10.3969/j.issn.1671-7414.2021.05.030]
　LI Ying,REN Bing-chen,HAN Xiao-qing,et al.Relationship between Serum MicroRNA-145 Expression with Lung Function,Airway Remodeling and Th1/Th2 Balance in Patients with Bronchial Asthma[J].Journal of Modern Laboratory Medicine,2021,36(03):133.[doi:10.3969/j.issn.1671-7414.2021.05.030]
[5]韩雪娇,刘红红,邢宁宁,等.支气管扩张伴支气管哮喘患者血清中microRNA-146水平表达与肺功能相关性分析[J].现代检验医学杂志,2022,37(02):100.[doi:10.3969/j.issn.1671-7414.2022.02.021]
　HAN Xue-jiao,LIU Hong-hong,XING Ning-ning,et al.Correlation Analysis between the Expression Level of micro RNA-146 in Serum and Lung Function in Patients with Bronchiectasis and Bronchial Asthma[J].Journal of Modern Laboratory Medicine,2022,37(03):100.[doi:10.3969/j.issn.1671-7414.2022.02.021]
[6]任婷婷,杨艳娥,马歆花,等.支气管哮喘急性期患儿血清VAMP2 水平表达及其临床意义[J].现代检验医学杂志,2023,38(05):175.[doi:10.3969/j.issn.1671-7414.2023.05.033]
　REN Tingting,YANG Yane,MA Xinhua,et al.Expression and Clinical Significance of Serum VAMP2 in Children with Bronchial Asthma at Acute Stage[J].Journal of Modern Laboratory Medicine,2023,38(03):175.[doi:10.3969/j.issn.1671-7414.2023.05.033]
[7]金吉明,吴艳杰,闫世林,等.慢性阻塞性肺疾病急性加重期患者血清甘油磷脂代谢物LPC18∶3，LPE 16∶1 水平变化与临床预后相关性研究[J].现代检验医学杂志,2024,39(04):93.[doi:10.3969/j.issn.1671-7414.2024.04.017]
　JIN Jiming,WU Yanjie,YAN Shilin,et al.Study on the Correlation between Changes in Serum Glycerophospholipid Metabolites LPC18∶3 and LPE 16∶1 Levels and Their Clinical Prognosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2024,39(03):93.[doi:10.3969/j.issn.1671-7414.2024.04.017]

备注/Memo

备注/Memo:
作者简介：黄明民（1998-），男，硕士研究生，医师，研究方向：慢性阻塞性肺疾病，E-mail：hmm15273186944@163.com。
更新日期/Last Update: 2024-05-15